This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Stoke Therapeutics stock | $45.02

Own Stoke Therapeutics stock in just a few minutes.


Fact checked

Stoke Therapeutics, Inc is a biotechnology business based in the US. Stoke Therapeutics shares (STOK) are listed on the NASDAQ and all prices are listed in US Dollars. Stoke Therapeutics employs 56 staff and has a market cap (total outstanding shares value) of USD$1.7 billion.

How to buy shares in Stoke Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Stoke Therapeutics. Find the stock by name or ticker symbol: STOK. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Stoke Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$45.02, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Stoke Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Stoke Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Stoke Therapeutics share price

Use our graph to track the performance of STOK stocks over time.

Stoke Therapeutics shares at a glance

Information last updated 2020-11-27.
Latest market close USD$45.02
52-week range USD$15.82 - USD$50
50-day moving average USD$41.1289
200-day moving average USD$31.064
Wall St. target price USD$48.13
PE ratio 21.6471
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-11.439

Buy Stoke Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Stoke Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Stoke Therapeutics price performance over time

Historical closes compared with the close of $45.02 from 2020-11-16

1 week (2020-11-25) -6.19%
1 month (2020-11-06) 12.92%
3 months (2020-09-04) 56.43%
6 months (2020-06-05) 82.64%
1 year (2019-12-05) 79.86%
2 years (2018-12-02) N/A
3 years (2017-12-02) N/A
5 years (2015-12-02) N/A

Is Stoke Therapeutics under- or over-valued?

Valuing Stoke Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Stoke Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Stoke Therapeutics's P/E ratio

Stoke Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Stoke Therapeutics shares trade at around 22x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Stoke Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -14.11%
Return on equity TTM -22.45%
Profit margin 0%
Book value $7.141
Market capitalisation USD$1.7 billion

TTM: trailing 12 months

Shorting Stoke Therapeutics shares

There are currently 2.9 million Stoke Therapeutics shares held short by investors – that's known as Stoke Therapeutics's "short interest". This figure is 1% down from 2.9 million last month.

There are a few different ways that this level of interest in shorting Stoke Therapeutics shares can be evaluated.

Stoke Therapeutics's "short interest ratio" (SIR)

Stoke Therapeutics's "short interest ratio" (SIR) is the quantity of Stoke Therapeutics shares currently shorted divided by the average quantity of Stoke Therapeutics shares traded daily (recently around 92480.220135966). Stoke Therapeutics's SIR currently stands at 30.89. In other words for every 100,000 Stoke Therapeutics shares traded daily on the market, roughly 30890 shares are currently held short.

However Stoke Therapeutics's short interest can also be evaluated against the total number of Stoke Therapeutics shares, or, against the total number of tradable Stoke Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Stoke Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Stoke Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.2252% of the tradable shares (for every 100,000 tradable Stoke Therapeutics shares, roughly 225 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Stoke Therapeutics.

Find out more about how you can short Stoke Therapeutics stock.

Stoke Therapeutics share dividends

We're not expecting Stoke Therapeutics to pay a dividend over the next 12 months.

Stoke Therapeutics overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site